PubRank

Claudia Sommerer

Author PubWeight™ 41.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010 5.50
2 Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015 4.78
3 Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011 2.82
4 Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012 1.47
5 Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008 1.42
6 The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant 2003 1.40
7 Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant 2008 1.39
8 Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008 1.34
9 Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011 1.27
10 FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007 1.21
11 The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant 2011 1.09
12 The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2011 1.00
13 Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2009 0.93
14 Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010 0.90
15 Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit 2016 0.86
16 Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010 0.84
17 The influence of immunosuppression on the development of BK virus nephropathy-- does it matter? Nephrol Dial Transplant 2007 0.84
18 Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010 0.84
19 Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. J Nephrol 2014 0.84
20 Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007 0.83
21 Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. Ther Drug Monit 2016 0.81
22 Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. Transplantation 2009 0.80
23 Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study. J Clin Periodontol 2011 0.79
24 Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin Nephrol 2015 0.79
25 Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl 2011 0.79
26 Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 2007 0.79
27 Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009 0.79
28 Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant 2008 0.78
29 Approaches towards individualized immune intervention. Dig Dis 2010 0.78
30 Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. Curr Pharm Des 2014 0.78
31 The extent of HLA-DR expression on HLA-DR(+) Tregs allows the identification of patients with clinically relevant borderline rejection. Transpl Int 2013 0.78
32 Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant 2010 0.77
33 A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. Clin Nephrol 2013 0.77
34 Does borderline kidney allograft rejection always require treatment? Transplantation 2010 0.76
35 Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients. Transpl Immunol 2012 0.76
36 Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. Transpl Int 2014 0.75
37 Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. Ther Drug Monit 2016 0.75
38 Hypercalcaemia-induced renal failure-a mystery. Nephrol Dial Transplant 2002 0.75
39 Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Expert Opin Pharmacother 2013 0.75
40 Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients
. Clin Nephrol 2016 0.75
41 Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. Ther Drug Monit 2016 0.75
42 Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clin Nephrol 2016 0.75
43 Absence of mismatch repair deficiency-related microsatellite instability in non-melanoma skin cancer. J Invest Dermatol 2011 0.75
44 Monitoring of calcineurin inhibitors by NFATregulated gene expression in de novo renal allograft recipients on cyclosporine A. Clin Nephrol 2015 0.75
45 Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adults. Ther Drug Monit 2012 0.75
46 Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. Transpl Int 2015 0.75